Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer

OBJECTIVE: Patients with BRAF-mutant colorectal cancer (CRC) have a poor prognosis. Molecular status is not currently used to select which drug to use in combination with radiotherapy. Our aim was to identify drugs that radiosensitise CRC cells with known BRAF status. METHODS: We screened 298 oncolo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Med
Main Authors: Carter, Rebecca, Cheraghchi-Bashi, Azadeh, Westhorpe, Adam, Yu, Sheng, Shanneik, Yasmin, Seraia, Elena, Ouaret, Djamila, Inoue, Yasuhiro, Koch, Catherine, Wilding, Jenny, Ebner, Daniel, Ryan, Anderson J., Buffa, Francesca M., Sharma, Ricky A.
Formato: Artigo
Idioma:Inglês
Publicado em: Chinese Anti-Cancer Association 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6713640/
https://ncbi.nlm.nih.gov/pubmed/31516745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20892/j.issn.2095-3941.2018.0284
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados